It has been shown that upregulation of MYC leads to increased surface expression of transferrin receptor (TfR) (O’Donnell et al., 2006), hence 89Zr-transferrin was developed as a potential probe for MYC status and tumor burden in several cancer models, such as prostate cancer and lymphoma (Holland et al., 2012; Doran et al., 2016). This evidence concerns the gene TFRC and prostate carcinoma.